Iris de Nie

72 C H A P T E R 5 Patient 1 Patient 2 Patient 3 Patient 4 Dose schedule n/a n/a switched to estradiol patches 100 mcg/24 hours twice a week switched to estradiol patches 100 mcg/24 hours twice a week Age stopped 31 18 41 32 Dose at cessation 100 mcg/24 hours twice a week 2 mg/day estrogel 0.06% 1.25 mg twice a day estradiol valerate 2 mg /twice a day Duration of oestrogen therapy (months) 22 6 216 99 Anti-androgen therapy Age started 28 18 23 24 Agent cyproterone acetate spironolactone cyproterone acetate cyproterone acetate Starting dose 25mg/day 100 mg/day; 1 mg/ day 100 mg/day 50 mg/day Dose schedule switched to 10 mg/day after 15 months n/a switched to 50 mg/day after 24 months Age stopped 31 18 41 32 Dose at cessation 10 mg/day 100 mg/day; 1 mg/ day 50 mg/day 50 mg/day Duration on anti- androgen (months) 17 6 216 93 Gender affirming surgery None None breast augmentation breast augmentation Physical response to hormone treatment Physical changes breast development, decreased muscle strength unknown unknown unknown Subsequent serum hormone levels - timing 20 months after commencement of estradiol n.d. 204 months after commencement of estradiol 93 months after commencement of hormones Estradiol (pmol/L) 641 n.d. 120 286 Testosterone (nmol/L) 0.4 n.d. 0.9 0.2 LH (IU/L) 0.1 n.d. 0.3 < 0.1 FSH (IU/L) n/d n.d. n.d. n.d.